Tosedostat

238750-77-1

C21H30N2O6

DMSO : 25 mg/mL (61.51 mM; Need ultrasonic and warming)

Metabolic Enzyme/Protease

Tosedostat is an aminopeptidase inhibitor. IC50 & Target: Aminopeptidase^[1] In Vitro: Treatment of HL-60 cells with Tosedostat (CHR-2797) leads to an increase in the secretion of Stanniocalcin 2 (STC2) protein into the growth medium. Increases in SLC7A11 expression are detectable at 60 nM Tosedostat and as early as 2 h posttreatment. The IC₅₀s for inhibition of proliferation by Tosedostat in U-937 and HuT 78 cell lines are 10 nM and >10 uM, respectively. Tosedostat treatment increases expression of amino acid deprivation response (AADR) genes in U-937 cells but not in HuT 78 cells^[1]. By 24 h with 0.01 uM Tosedostat the mean MCA production is reduced to 77.8% of the untreated control cells; similarly the MCA production is reduced to 51.3% with 1 uM, 38.5% with 5 uM, and 35.3% with 10 uM Tosedostat^[2]. In Vivo: Tosedostat (CHR-2797) is active as an anticancer agent in vivo in rodent cancer models, and a dose-response relationship has been shown in two models. The effect of Tosedostat is less apparent when the tumor burden is higher before treatment^[1].